Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

METABOLIGHT

Financiado

Cerrado

Optical imaging platform to unravel metabolic reprogramming of cancer a path fo...

Optical imaging platform to unravel metabolic reprogramming of cancer a path for improved treatments "Recent investigations revealed that cancer tissue possesses several important metabolic features, such as differential utilization of many essential metabolites. This phenomenon is now referred to as ""metabolic reprogramming"" a... ver más

31/05/2025

SWISSLUMIX SARL

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

SWISSLUMIX SARL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-02-12

ERC-2019-COG: ERC Consolidator Grant Scope:Objectives

I+D

Cerrada hace 6 años

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

SWISSLUMIX SARL

2.00M€ | Lider

JUICE AND WORLD

184.00K€ | Participante

EPFL

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 63 meses Fecha Inicio: 2020-02-12
Fecha Fin: 2025-05-31

Líder del proyecto

SWISSLUMIX SARL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "Recent investigations revealed that cancer tissue possesses several important metabolic features, such as differential utilization of many essential metabolites. This phenomenon is now referred to as ""metabolic reprogramming"" and is known to be required for malignant transformation, tumor development, invasion and metastasis. Its complex and dynamic nature has been recognized as one of the major challenges for effective cancer treatment. Therefore, a better understanding of metabolic dependencies in specific tumor types can provide a path for improved cancer treatments. However, no efficient methodologies currently exist that allow noninvasive imaging and quantification of the uptake of essential metabolites in animal models of disease. Current strategies rely on either nuclear imaging techniques such as PET/SPECT/MRI or endpoint ex vivo quantification of metabolites (ex. MS). All of these methods have significant limitations, resulting in a lack of understanding of tumor metabolism and, consequently, poor predictability and efficacy of cancer therapies. To address the unmet need for nutrient uptake imaging tools, we propose to develop a novel platform based on a combination of versatile click chemistry reactions with noninvasive, ultrasensitive bioluminescent imaging techniques. The applications of the novel platform will focus on tumor uptake measurements of glucose, fatty acids, amino acids, and nucleosides previously reported to play important roles in cancer metabolism. We will then use this platform to investigate the metabolic reprogramming of different liver cancers, which may lead to the generation of novel, effective treatments; therefore, this novel platform has high clinical applicability. Due to its versatile nature, application of the platform can be expended to studies of many other important human pathologies in which changes in metabolism play a key role, such as diabetes, neurodegenerative diseases, nonalcoholic steatohepatitis, and many others"

Conecta tu I+D

Entra hoy

Forgot your password?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores